-
Tytuł:
-
Diagnostic Significance of 3D Automated Breast Volume Scanner in a Combination with Contrast-Enhanced Ultrasound for Breast Cancer.
-
Autorzy:
-
Yuan Q; Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
Song C; Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
Tian Y; Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
Chen N; Department of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
He X; Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
Wang Y; Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
Han P; Department of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China.
-
Źródło:
-
BioMed research international [Biomed Res Int] 2022 Aug 03; Vol. 2022, pp. 3199884. Date of Electronic Publication: 2022 Aug 03 (Print Publication: 2022).
-
Typ publikacji:
-
Journal Article; Retracted Publication
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: New York, NY : Hindawi Pub. Co.
-
MeSH Terms:
-
Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/pathology
Ultrasonography, Mammary*/methods
Breast/diagnostic imaging ; Female ; Humans ; Reproducibility of Results ; Ultrasonography
-
References:
-
Clin Breast Cancer. 2022 Feb;22(2):e142-e146. (PMID: 34219020)
Thorac Cancer. 2021 Nov;12(21):2849-2856. (PMID: 34605207)
Ultrasound Med Biol. 2018 Jan;44(1):37-70. (PMID: 29107353)
Breast. 2020 Oct;53:8-17. (PMID: 32540554)
J Magn Reson Imaging. 2019 Aug;50(2):377-390. (PMID: 30659696)
Ultrasound Med Biol. 2021 Jun;47(6):1475-1483. (PMID: 33714619)
Cancer Imaging. 2021 Mar 12;21(1):28. (PMID: 33712074)
Radiology. 2021 Apr;299(1):36-48. (PMID: 33650905)
BMC Med Imaging. 2020 Jun 17;20(1):66. (PMID: 32552678)
J Pers Med. 2021 Jul 23;11(8):. (PMID: 34442347)
J Healthc Eng. 2021 Oct 1;2021:9591670. (PMID: 34631001)
Pharm Res. 2020 Jul 14;37(7):145. (PMID: 32666304)
Clin Hemorheol Microcirc. 2018;70(3):291-300. (PMID: 29710688)
Theranostics. 2021 Sep 21;11(19):9557-9570. (PMID: 34646386)
J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. (PMID: 29371086)
Clin Imaging. 2021 Jan;69:269-279. (PMID: 33032103)
Eur Radiol. 2019 Apr;29(4):1762-1777. (PMID: 30255244)
Ultrasound Med Biol. 2019 Aug;45(8):1865-1873. (PMID: 31101445)
J Int Med Res. 2021 May;49(5):3000605211010619. (PMID: 33978517)
Ultraschall Med. 2019 Apr;40(2):194-204. (PMID: 30103213)
Behav Neurol. 2022 Apr 11;2022:7725597. (PMID: 35449792)
Ultrason Imaging. 2020 Nov;42(6):261-270. (PMID: 33019918)
-
Entry Date(s):
-
Date Created: 20220815 Date Completed: 20220816 Latest Revision: 20240117
-
Update Code:
-
20240117
-
PubMed Central ID:
-
PMC9365610
-
DOI:
-
10.1155/2022/3199884
-
PMID:
-
35968241
-
The incidence of cancer is increasing today, particularly lung and chest cancer. Employing novel methods to detect cancer in its earliest stages and discover painless, noninvasive treatments are urgently needed. The goal of the proposed study is to investigate the value of automated breast volume scanning (ABUS) in conjunction with contrast-enhanced ultrasonography (CEUS) in properly diagnosing breast cancer in its early stages and the effectiveness of neoadjuvant chemotherapy (NAC) in treating the disease. For the research study, information on 98 patients who had NAC and surgery in the breast surgery department of the Shaanxi Provincial Cancer Hospital has been gathered. All patients have received four cycles of NAC and underwent conventional ultrasound (HUSS), CEUS, ABUS, and pathological examination. At the same time, receiver operating characteristic (ROC) curve analysis, single factor, multiple linear regression, and other methods have also been used to analyze the diagnostic efficacy of breast cancer and NAC efficacy evaluation results. The study of this paper is totally based on the data collected from Shaanxi Provincial Cancer Hospital. The statistical and computational analyses are performed on the data collected for drawing inferences. When the findings are compared to the results of the pathological examination, HUSS has demonstrated a significant distinction between benign and malignant diagnoses with a statistical value of P < 0.05.ABUS combined with CEUS has shown no considerable differences in correlation study. Except for negative likelihood ratio, the diagnostic performance indexes of CEUS+ ABUS are substantially higher than HHUS with P < 0.05. ROC curve analysis is also performed which shows that CEUS and ABUS combination has higher precision in the analysis of breast cancer. ABUS pooled with CEUS shows great application value in the judgment of breast cancer as per the results obtained from the statistical analysis on data of 98 patients.
Competing Interests: The authors have nothing to declare as conflicts of interest.
(Copyright © 2022 Quan Yuan et al.)
Retraction in: Biomed Res Int. 2024 Jan 9;2024:9846951. (PMID: 38230081)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
